vs
Side-by-side financial comparison of BIOLIFE SOLUTIONS INC (BLFS) and CONMED Corp (CNMD). Click either name above to swap in a different company.
CONMED Corp is the larger business by last-quarter revenue ($373.2M vs $18.8M, roughly 19.9× BIOLIFE SOLUTIONS INC). On growth, BIOLIFE SOLUTIONS INC posted the faster year-over-year revenue change (24.3% vs 7.9%). Over the past eight quarters, CONMED Corp's revenue compounded faster (9.3% CAGR vs 1.0%).
Biolife Solutions Inc. develops, manufactures and distributes specialized biopreservation products and cold chain management solutions for the cell and gene therapy, biopharmaceutical and regenerative medicine industries. It offers cryopreservation media, automated thawing systems, and temperature monitoring tools, serving biotech firms, research institutions and clinical labs globally.
The CONMED Corporation is a publicly traded American manufacturer of medical equipment and surgical devices, primarily in the orthopedic, laparoscopic and general surgery, and patient care areas. CONMED's headquarters is in Largo, Florida. Prior to July 2022, it was in Utica, New York. CONMED embraces a people-first culture that starts with a mission to support their healthcare partners and the patients they serve. They have manufacturing facilities in the United States and Mexico, offices in...
BLFS vs CNMD — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $18.8M | $373.2M |
| Net Profit | $11.1M | — |
| Gross Margin | — | 58.5% |
| Operating Margin | 7.2% | 9.8% |
| Net Margin | 58.9% | — |
| Revenue YoY | 24.3% | 7.9% |
| Net Profit YoY | -11.1% | — |
| EPS (diluted) | $0.23 | $0.54 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.8M | $373.2M | ||
| Q3 25 | $28.1M | $337.9M | ||
| Q2 25 | $25.4M | $342.3M | ||
| Q1 25 | $23.9M | $321.3M | ||
| Q4 24 | $15.1M | $345.9M | ||
| Q3 24 | $21.4M | $316.7M | ||
| Q2 24 | $19.7M | $332.1M | ||
| Q1 24 | $18.4M | $312.3M |
| Q4 25 | $11.1M | — | ||
| Q3 25 | $621.0K | $2.9M | ||
| Q2 25 | $-15.8M | $21.4M | ||
| Q1 25 | $-448.0K | $6.0M | ||
| Q4 24 | $12.5M | — | ||
| Q3 24 | $-1.7M | $49.0M | ||
| Q2 24 | $-20.7M | $30.0M | ||
| Q1 24 | $-10.2M | $19.7M |
| Q4 25 | — | 58.5% | ||
| Q3 25 | — | 49.2% | ||
| Q2 25 | — | 55.0% | ||
| Q1 25 | — | 55.3% | ||
| Q4 24 | — | 57.3% | ||
| Q3 24 | — | 56.5% | ||
| Q2 24 | — | 55.3% | ||
| Q1 24 | — | 55.1% |
| Q4 25 | 7.2% | 9.8% | ||
| Q3 25 | -0.3% | 3.5% | ||
| Q2 25 | -65.5% | 11.1% | ||
| Q1 25 | -5.1% | 5.0% | ||
| Q4 24 | 3.6% | 15.2% | ||
| Q3 24 | -2.0% | 20.7% | ||
| Q2 24 | -6.6% | 14.2% | ||
| Q1 24 | -17.9% | 11.2% |
| Q4 25 | 58.9% | — | ||
| Q3 25 | 2.2% | 0.8% | ||
| Q2 25 | -62.3% | 6.3% | ||
| Q1 25 | -1.9% | 1.9% | ||
| Q4 24 | 82.5% | — | ||
| Q3 24 | -8.0% | 15.5% | ||
| Q2 24 | -105.1% | 9.0% | ||
| Q1 24 | -55.4% | 6.3% |
| Q4 25 | $0.23 | $0.54 | ||
| Q3 25 | $0.01 | $0.09 | ||
| Q2 25 | $-0.33 | $0.69 | ||
| Q1 25 | $-0.01 | $0.19 | ||
| Q4 24 | $0.27 | $1.09 | ||
| Q3 24 | $-0.04 | $1.57 | ||
| Q2 24 | $-0.45 | $0.96 | ||
| Q1 24 | $-0.22 | $0.63 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $33.0M | — |
| Total DebtLower is stronger | $5.0M | $834.2M |
| Stockholders' EquityBook value | $371.9M | $1.0B |
| Total Assets | $405.9M | $2.3B |
| Debt / EquityLower = less leverage | 0.01× | 0.81× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $33.0M | — | ||
| Q3 25 | $29.5M | — | ||
| Q2 25 | $31.9M | — | ||
| Q1 25 | $66.9M | — | ||
| Q4 24 | $91.5M | — | ||
| Q3 24 | $24.0M | — | ||
| Q2 24 | $22.0M | — | ||
| Q1 24 | $29.7M | — |
| Q4 25 | $5.0M | $834.2M | ||
| Q3 25 | $7.5M | $853.0M | ||
| Q2 25 | $10.1M | $881.1M | ||
| Q1 25 | $12.9M | $891.4M | ||
| Q4 24 | $15.9M | $905.1M | ||
| Q3 24 | $20.1M | $940.1M | ||
| Q2 24 | $21.1M | $965.2M | ||
| Q1 24 | $24.3M | $990.1M |
| Q4 25 | $371.9M | $1.0B | ||
| Q3 25 | $353.7M | $1.0B | ||
| Q2 25 | $347.2M | $1.0B | ||
| Q1 25 | $352.6M | $977.6M | ||
| Q4 24 | $348.9M | $962.7M | ||
| Q3 24 | $325.5M | $932.9M | ||
| Q2 24 | $321.4M | $881.8M | ||
| Q1 24 | $333.4M | $854.7M |
| Q4 25 | $405.9M | $2.3B | ||
| Q3 25 | $392.1M | $2.3B | ||
| Q2 25 | $387.2M | $2.3B | ||
| Q1 25 | $395.1M | $2.3B | ||
| Q4 24 | $399.5M | $2.3B | ||
| Q3 24 | $381.7M | $2.3B | ||
| Q2 24 | $375.0M | $2.3B | ||
| Q1 24 | $401.6M | $2.3B |
| Q4 25 | 0.01× | 0.81× | ||
| Q3 25 | 0.02× | 0.85× | ||
| Q2 25 | 0.03× | 0.88× | ||
| Q1 25 | 0.04× | 0.91× | ||
| Q4 24 | 0.05× | 0.94× | ||
| Q3 24 | 0.06× | 1.01× | ||
| Q2 24 | 0.07× | 1.09× | ||
| Q1 24 | 0.07× | 1.16× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.9M | $46.3M |
| Free Cash FlowOCF − Capex | — | $41.2M |
| FCF MarginFCF / Revenue | — | 11.0% |
| Capex IntensityCapex / Revenue | — | 1.4% |
| Cash ConversionOCF / Net Profit | 0.44× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $150.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.9M | $46.3M | ||
| Q3 25 | $6.1M | $53.7M | ||
| Q2 25 | $7.4M | $29.1M | ||
| Q1 25 | $1.7M | $41.5M | ||
| Q4 24 | $1.6M | $43.3M | ||
| Q3 24 | $4.8M | $51.2M | ||
| Q2 24 | $6.5M | $43.3M | ||
| Q1 24 | $-4.5M | $29.1M |
| Q4 25 | — | $41.2M | ||
| Q3 25 | — | $48.5M | ||
| Q2 25 | — | $23.4M | ||
| Q1 25 | — | $37.8M | ||
| Q4 24 | — | $39.3M | ||
| Q3 24 | — | $47.8M | ||
| Q2 24 | — | $39.7M | ||
| Q1 24 | — | $27.1M |
| Q4 25 | — | 11.0% | ||
| Q3 25 | — | 14.4% | ||
| Q2 25 | — | 6.8% | ||
| Q1 25 | — | 11.8% | ||
| Q4 24 | — | 11.4% | ||
| Q3 24 | — | 15.1% | ||
| Q2 24 | — | 12.0% | ||
| Q1 24 | — | 8.7% |
| Q4 25 | — | 1.4% | ||
| Q3 25 | — | 1.5% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 1.2% | ||
| Q3 24 | — | 1.1% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 0.7% |
| Q4 25 | 0.44× | — | ||
| Q3 25 | 9.83× | 18.78× | ||
| Q2 25 | — | 1.36× | ||
| Q1 25 | — | 6.88× | ||
| Q4 24 | 0.13× | — | ||
| Q3 24 | — | 1.05× | ||
| Q2 24 | — | 1.44× | ||
| Q1 24 | — | 1.48× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLFS
Segment breakdown not available.
CNMD
| Transferred At Point In Time | $358.5M | 96% |
| Transferred Over Time | $14.7M | 4% |
